Workflow
ADMA Biologics(ADMA)
icon
Search documents
Titanium Metal Market Report 2024: Trends, Analysis and Forecast (2018-2030) Featuring Extensive Profiles of ADMA Products, Precision Castparts, Ametek, Avista, Cristal, and More
GlobeNewswire News Room· 2024-06-05 08:38
Dublin, June 05, 2024 (GLOBE NEWSWIRE) -- The "Titanium Metal Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The global titanium metal market is expected to reach an estimated $2.4 billion by 2030 with a CAGR of 5.8% from 2024 to 2030.The major drivers for this market are rising use of titanium dioxide in the paints & coating industry, growing use of titanium metal in the aerospace & defense industry, as well as, increasing deman ...
5 Stocks With Recent Price Strength to Tap May's Rally
Zacks Investment Research· 2024-05-15 13:06
The 15-month bull run of U.S. stock markets suffered a surprise setback in April. We believe that April’s meltdown was nothing but a bull market correction, and this time a welcome one, as Wall Street has rebounded in May.The Department of Labor reported that the U.S. economy added 175,000 jobs in April, missing the consensus estimate of 200,000. Job additions in March were revised upward by 12,000 while those in February were revised downward by 34,000. The unemployment rate increased to 3.9% in April, com ...
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
Zacks Investment Research· 2024-05-13 14:46
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adma Biologics (ADMA) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Adma Biologics is a member of the Medical sector. This group includes 1048 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank considers 1 ...
ADMA Biologics(ADMA) - 2024 Q1 - Earnings Call Transcript
2024-05-10 03:11
ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2024 Earnings Conference Call May 9, 2024 4:30 AM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - President and CEO Brian Lenz - Executive Vice President, Chief Financial Officer and General Manager, ADMA BioCenters Conference Call Participants Anthony Petrone - Mizuho Group Kristen Kluska - Cantor Fitzgerald Gary Nachman - Raymond James Operator Good afternoon, and welcome to the ADMA Biologics First Q ...
Adma Biologics (ADMA) Surpasses Q1 Earnings and Revenue Estimates
Zacks Investment Research· 2024-05-09 23:21
Adma Biologics (ADMA) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 60%. A quarter ago, it was expected that this infectious disease drug developer would post earnings of $0.02 per share when it actually produced earnings of $0.04, delivering a surprise of 100%.Over the last four quarte ...
ADMA Biologics(ADMA) - 2024 Q1 - Quarterly Report
2024-05-09 21:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36728 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2590442 (State o ...
ADMA Biologics(ADMA) - 2024 Q1 - Quarterly Results
2024-05-09 20:06
Exhibit 99.1 ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update 1Q 2024 Total Revenue of $81.9 Million, a 44% Increase Y-o-Y 1Q 2024 GAAP Net Income of $17.8 Million, a $24.6 Million Increase Y-o-Y 1Q 2024 Adjusted EBITDA(1) of $26.4 Million, a 970% Increase Y-o-Y FY 2024 and 2025 Total Revenue Guidance Increased to More Than $355 Million and $410 Million, Respectively FY 2024 Net Income Guidance Increased to More Than $85 Million and Adjusted EBITDA Guidance Increase ...
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?
Zacks Investment Research· 2024-04-30 14:35
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Adma Biologics (ADMA) .Adma Biologics currently has an average brokerage r ...
What's in Store for ADMA Biologics (ADMA) in Q1 Earnings?
Zacks Investment Research· 2024-04-29 16:31
We expect investors to focus on the sales performance of ADMA Biologics, Inc.’s (ADMA) portfolio of its three marketed commercial products and other pipeline updates when it reports first-quarter 2024 results.Let’s see how things have shaped up for the quarter to be reported.Factors at PlayADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases. The company’s top line currently comprises sales of three FDA-approved products, ...
3 'Buy-Rated' Biotech Stocks Under $10
Seeking Alpha· 2024-04-28 08:39
tazytaz/E+ via Getty Images Today, we are going to do something different to close out another trading week. In this column, I highlight three biotech stocks with favorable risk/reward profiles and that are trading for under ten bucks a share. Let's start with ADMA Biologics, Inc. (ADMA). This company is focused on manufacturing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. ADMA Biologics recently brought online the last of 10 large plasma collection fa ...